Foundation Fighting Blindness CRO Talks Luxturna

Friday, October 13, 2017

The U.S. FDA’s Cellular, Tissue and Gene Therapies Advisory Committee met to review the data presented by Spark Therapeutics as the company continues its attempts to obtain approval of Luxturna (voretigene neparvovec) to treat vision loss caused by a mutation in the RPE65 gene. Read Dr. Rose's interview with Rare Disease Report here, discussing Luxturna, its mechanism of action, and why the FDA’s review of it is so vital to patient’s suffering from retinal diseases.